Prognostic value of EZH2 expression and activity in renal cell carcinoma: A prospective study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Liu, Li ^a   Xu, Zhibing ^a   Zhong, Lei ^a   Wang, Hang ^a   Jiang, Shuai ^a   Long, Qilai ^a   Xu, Jiejie ^b   Guo, Jianming ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HISTONE; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; WESTERN BLOTTING; CARCINOMA, RENAL CELL; DISEASE COURSE; GENE EXPRESSION REGULATION; KIDNEY NEOPLASMS; METABOLISM; RISK ASSESSMENT;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84896727282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081484     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
2. Ruutu M BP, Taari K (2008) Resection of renal cell cancer metastases: where do we stand in 2008? Eur Urol Suppl 7: 436-442. doi:10.1016/j.eursup.2008. 01.005.
3. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W (2007) TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8: 554-558. doi:10.1016/S1470-2045(07)70173-0. PubMed: 17540307.
4. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY et al. (2012) State of the science: an update on renal cell carcinoma. Mol Cancer Res 10: 859-880. doi:10.1158/1541-7786.MCR-12-0117. PubMed: 22638109.
5. Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H et al. (2010) Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70: 4287-4291. doi:10.1158/0008- 5472.CAN-10-0120. PubMed: 20501857.
6. Niu X, Zhang T, Liao L, Zhou L, Lindner DJ et al. (2012) The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31: 776-786. doi:10.1038/onc.2011.266. PubMed: 21725364.
7. Jacobs JJ, van Lohuizen M (1999) Cellular memory of transcriptional states by Polycomb-group proteins. Semin Cell Dev Biol 10: 227-235. doi:10.1006/scdb.1999.0304. PubMed: 10441076.
8. Francis NJ, Kingston RE (2001) Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol 2: 409-421. doi:10.1038/35073039. PubMed: 11389465.
9. Martinez AM, Cavalli G (2006) The role of polycomb group proteins in cell cycle regulation during development. Cell Cycle 5: 1189-1197. doi:10.4161/cc.5.11.2781. PubMed: 16721063.
10. Sauvageau M, Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299-313. doi:10.1016/j.stem.2010.08.002. PubMed: 20804967.
11. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629. doi:10.1038/nature01075. PubMed: 12374981.
12. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273. PubMed: 16330673.
13. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A et al. (2012) EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26: 439-444. doi:10.1101/gad.181800.111. PubMed: 22391448.
14. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663. doi:10.1097/00000478-198210000-00007. PubMed: 7180965.
15. Eble JN SG, Epstein JI (2004) Pathology and genetics of tumours of the urinary system and male genital organs. France: IARC Press.
16. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474. doi:10.1245/s10434-010-0985-4. PubMed: 20180029.
17. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP et al. (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148. doi:10.1016/S1470-2045(08)70004-4. PubMed: 18207460.
18. Liu H, Xu J, Zhou L, Yun X, Chen L et al. (2011) Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res 71: 7547-7557. doi:10.1158/0008-5472.CAN-11-2260. PubMed: 21994334.
19. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33. doi:10.1038/nrg1748. PubMed: 16369569.
20. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856. doi:10.1038/nrc1991. PubMed: 17060944.
21. Moss TJ, Wallrath LL (2007) Connections between epigenetic gene silencing and human disease. Mutat Res 618: 163-174. doi:10.1016/j.mrfmmm.2006.05.038. PubMed: 17306846.
22. Cao R, Zhang Y (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155-164. doi:10.1016/j.gde. 2004.02.001. PubMed: 15196462.
23. Ringrose L, Paro R (2004) Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38: 413-443. doi:10.1146/annurev.genet.38.072902.091907. PubMed: 15568982.
24. Dalkilic E, Filiz G, Yavuz M, Dilek K, Ersoy A et al. (2013) Ki-67 proliferation index in renal biopsy samples of patients with systemic lupus erythematosus and its correlation with clinical findings. Iran J Kidney Dis 7: 198-203. PubMed: 23689151.
25. Hinz S, Weikert S, Magheli A, Hoffmann M, Engers R et al. (2009) Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol 182: 2920-2925. doi:10.1016/j.juro.2009.08.014. PubMed: 19846140.
26. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874. PubMed: 16357870.
27. van der Vlag J, Otte AP (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474-478. doi:10.1038/70602. PubMed: 10581039.
28. Hong S, Cho YW, Yu LR, Yu H, Veenstra TD et al. (2007) Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A 104: 18439-18444. doi:10.1073/pnas.0707292104. PubMed: 18003914.
29. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J et al. (2012) A review of integrated staging systems for renal cell carcinoma. Eur Urol 62: 303-314. doi:10.1016/j.eururo.2012.04.049. PubMed: 22575911.
30. Furge KA, MacKeigan JP, Teh BT (2010) Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 11: 571-578. doi:10.1016/S1470-2045(09)70380-8. PubMed: 20381423.